Response to: 'Lack of standardization of ANA and implications for drug development and precision medicine' by Mahler

Ann Rheum Dis. 2019 May;78(5):e34. doi: 10.1136/annrheumdis-2018-213399. Epub 2018 Mar 28.

Authors

David S Pisetsky¹, Diane M Spencer¹, Peter E Lipsky², Brad H Rovin³

Affiliations

¹ Department of Medicine and Immunology, Duke University Medical Center and Medical Research Service, VA Medical Center, Durham, North Carolina, USA.
² RILITE Research Institute, Charlottesville, Virginia, USA.
³ Division of Nephrology, Wexner Medical Center, The Ohio State University, Columbus, Ohio, USA.

PMID: 29592916
DOI: 10.1136/annrheumdis-2018-213399

No abstract available

Keywords: rheumatoid arthritis; systemic lupus erythematosus; treatment.

Publication types

Letter
Comment

MeSH terms

Antibodies, Antinuclear*
Drug Development
Humans
Patients
Precision Medicine*
Reference Standards

Substances

Antibodies, Antinuclear